Please login to the form below
Neovii Pharmaceuticals promotes Juergen Pohle to CEO
He will take over from Alexandre Sudarskis in January
Swiss biopharmaceutical company Neovii Pharmaceuticals has promoted its chief commercial officer Juergen Pohle to managing director and CEO.
He will assume the new role in January, when it takes over from outgoing CEO Alexandre Sudarskis who will continue at the firm as an executive director and member of its board.
David Fuhrer said: "Juergen's leadership skills, his long-term proven track record and his many years of international experience in the pharmaceutical industry make him the ideal candidate for the position of CEO.
“We are extremely pleased that Juergen has embraced the challenge of further driving the development and growth of Neovii."
Pohle has served as Neovii’s chief commercial officer of Pharmaceuticals since 2016 and has over 25 years of experience in the pharmaceutical industry, having previously worked at Bayer HealthCare, GlaxoSmithKline and Novartis.
Prior to joining Neovii he headed up Novartis’ emerging growth markets and institutional customers businesses.
Subscribe to our email news alerts
- Pfizer’s RSV vaccine granted MHRA approval to protect infants and older adults
- Novavax’s updated COVID-19 vaccine granted Emergency Use Listing by WHO
- FDA to investigate risk of T-cell malignancy from CAR-T cell immunotherapies
- Boehringer Ingelheim and IBM announce AI antibody drug discovery partnership
- New blood test to reduce heart attacks and death rates in A&E heart patients
- Clairvoyant commercialisation
No results were found
PMHub
Springer Nature
Did you know that we publish over 3,000 journals, and that over 1,000 of those are clinical science journals? Promote...
Latest intelligence
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
- The rise of digital healthcare – fuelled by open innovation in healthtech hubs
- How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of drug development...
